AstraZeneca Tries For Seroquel XR Approvals In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.
You may also be interested in...
AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.
AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.
AstraZeneca Submits Seroquel XR sNDA For Major Depressive Disorder
Firm looks to expand $4 billion franchise into lucrative MDD market.